14/10/2026
Lexeo Therapeutics is conducting a late-stage clinical trial to evaluate whether the investigational gene therapy, LX2006, may improve heart function and limit the progression of Friedreich ataxia cardiomyopathy (FA-CM).
The study is a global study with multiple locations across the U.S. and will first enroll individuals aged 16 years and older, followed by children aged 6 to under 16 years of age.
If you are a diagnosed individual or caregiver who would like to learn more about this trial, visit: https://trials.lexeotx.com/clinical-trials/sunrise-fa2/